Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer

Akeso announced the first patient has been dosed in its Phase II study (AK146D1-202) evaluating AK146D1, an internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate. The update is an early clinical milestone with no interim efficacy/safety results disclosed, but it modestly improves near-term development momentum for the program.

Analysis

Akeso announced the first patient has been dosed in its Phase II study (AK146D1-202) evaluating AK146D1, an internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate. The update is an early clinical milestone with no interim efficacy/safety results disclosed, but it modestly improves near-term development momentum for the program.